Svs5 Inhibitors
Svs5 inhibitors belong to a class of chemical compounds specifically designed to interact with and inhibit the activity of a particular enzyme or protein referred to as Svs5. The designation Svs5 typically corresponds to a specific nomenclature used to identify this target within a larger biochemical or molecular context, which may be integral to a particular biochemical pathway or cellular process. These inhibitors are often the result of targeted medicinal chemistry efforts, where the goal is to create molecules that can bind to the active site, or a regulatory site, of the Svs5 enzyme, thereby modulating its function. The design of Svs5 inhibitors leverages principles of molecular recognition, where the inhibitor's shape, electrostatic surface, and hydrophobic or hydrophilic properties are optimized to interact with corresponding features on the Svs5 enzyme.
The development of Svs5 inhibitors typically involves a deep understanding of the structure and function of the Svs5 enzyme. This could be achieved through various techniques such as X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy, which provide a detailed three-dimensional structure of the enzyme. Researchers use this structural information to identify potential binding sites and to understand the enzyme's mechanism of action at the molecular level. Computational methods, like molecular docking and virtual screening, play a crucial role in simulating how potential inhibitors might interact with the enzyme. These in silico techniques can rapidly evaluate thousands of compounds, predicting their binding affinity and specificity towards the Svs5 enzyme. Once potential inhibitors are identified, they can be synthesized and tested in vitro to confirm their inhibitory effects. The chemical properties of these inhibitors can be further refined through iterative processes of design, synthesis, and testing to improve their potency and selectivity for the Svs5 enzyme.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR (mechanistic target of rapamycin), which is crucial for protein synthesis and cell growth. As mTOR can regulate protein synthesis and cellular growth, its inhibition by rapamycin indirectly decreases the functional activity of Svs5 if Svs5 is involved in these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K (phosphoinositide 3-kinases), which is upstream of the Akt/mTOR pathway. PI3K inhibition would reduce Akt phosphorylation, leading to a downstream reduction in mTOR activity and potentially hindering cellular processes that could affect Svs5 functionality. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a chemical that inhibits PI3K, blocking the PI3K/Akt signaling pathway. This action may result in reduced activity of downstream targets such as mTOR, which might indirectly decrease the functional activity of Svs5 if it is involved in growth and survival pathways mediated by this signaling route. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is a part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can prevent the phosphorylation and activation of ERK, potentially leading to the downregulation of cellular processes that may involve Svs5. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of MAPK/ERK pathway. The inhibition of this pathway can alter transcription factors and gene expression, potentially affecting the functional activity of Svs5 if it is involved in signaling cascades regulated by ERK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in stress and inflammatory responses. Inhibition of p38 MAP kinase could modify transcriptional programs and cellular responses where Svs5 might play a role. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which participates in the regulation of apoptosis, cell proliferation, and inflammation. Interference with JNK signaling could indirectly affect Svs5 activity if it is implicated in these cellular processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src kinase inhibitor that also inhibits other tyrosine kinases. Src family kinases are involved in various cellular processes, including cell growth and differentiation, and their inhibition could affect the pathways where Svs5 is active. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases, which are involved in signaling pathways that regulate diverse cellular functions. By inhibiting Src kinases, PP2 could potentially decrease the functional activity of Svs5 through these signaling routes. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits the tyrosine kinase domains of both EGFR and HER2/neu, which are critical for cell signaling related to growth and proliferation. If Svs5 is involved in pathways downstream of EGFR or HER2/neu, its activity could be indirectly diminished by such inhibition. | ||||||